Currently, there are 70.69M common shares owned by the public and among those 57.57M shares have been available to trade.
The company’s stock has a 5-day price change of -74.53% and -71.08% over the past three months. OVID shares are trading -75.48% year to date (YTD), with the 12-month market performance down to -77.94% lower. It has a 12-month low price of $2.57 and touched a high of $4.14 over the same period. OVID has an average intraday trading volume of 189.38K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -74.47%, -74.74%, and -76.39% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Ovid Therapeutics Inc (NASDAQ: OVID) shares accounts for 60.18% of the company’s 70.69M shares outstanding.
It has a market capitalization of $56.01M and a beta (3y monthly) value of 0.55. The earnings-per-share (ttm) stands at -$0.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.89% over the week and 6.88% over the month.
Earnings per share for the fiscal year are expected to decrease by -11.15%, and 35.36% over the next financial year.
Looking at the support for the OVID, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on April 30, 2024, with the firm’s price target at $9. H.C. Wainwright coverage for the Ovid Therapeutics Inc (OVID) stock in a research note released on April 29, 2024 offered a Buy rating with a price target of $9. Wedbush was of a view on April 05, 2024 that the stock is Outperform, while BTIG Research gave the stock Buy rating on December 21, 2023, issuing a price target of $11. Oppenheimer on their part issued Outperform rating on October 13, 2023.
